Atara Biotherapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. (ATRA) on June 22, 2026, covering events occurring between June 22 and June 26, 2026. The filing addresses significant changes in the Company's executive leadership regarding its financial and accounting functions.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of Chief Accounting Officer: Yanina Grant-Huerta was notified on June 22, 2026, that her employment as Chief Accounting Officer will end effective July 17, 2026.
- Appointment of Interim CFO: On June 26, 2026, the Board appointed Kevin G. Sarney as Interim Chief Financial Officer, effective immediately. Mr. Sarney will also serve as the Company's principal financial officer and principal accounting officer.
- Compensation Structure: Mr. Sarney's services are provided through a consulting agreement with Charles River CFO, Inc. (CRCFO). The Company will pay CRCFO an agreed hourly rate; Mr. Sarney will not receive direct compensation from Atara Biotherapeutics.
Outlook, Risks, and Management Commentary
Management has secured interim leadership with Mr. Sarney, who brings over 25 years of finance and accounting experience in the life sciences sector, including prior executive roles and auditing experience at PricewaterhouseCoopers. The consulting agreement allows for termination by either party with 30 days' written notice. No related person transactions or family relationships involving Mr. Sarney were disclosed.
Investor Verification Checklist
- Verify the transition timeline for the Chief Accounting Officer role between July 17, 2026, and the full integration of the interim CFO.
- Confirm the specific hourly rate and estimated total cost of the consulting agreement with CRCFO in future filings.
- Monitor for any subsequent announcements regarding a permanent Chief Financial Officer appointment.
- Review upcoming quarterly reports for any impact on financial reporting timelines due to the leadership transition.